RP-HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-04. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
== Metrology == A number of reference materials are available for silver nanoparticles. NIST RM 8017 contains 75 nm silver nanoparticles embedded in a cake of the polymer polyvinylpyrrolidone to stabilize them against oxidation for a long shelf life. They have reference values for mean particle size using dynamic light scattering, ultra-small-angle X-ray scattering, atomic force microscopy, and transmission electron microscopy; and size distribution reference values for the latter two methods. The BAM-N001 certified reference material contains silver nanoparticles with a specified size distribution with a number-weighted median size of 12.6 nm measured by small-angle X-ray scattering and transmission electron microscopy.
=== Economics === The nearly decade and a half of wars greatly weakened the Spanish American economies and political institutions, which hindered the region's potential economic development for most of the nineteenth century and resulted in the enduring instability the region experienced. Independence destroyed the de facto trade bloc that was the Spanish Empire – Manila galleons and Spanish treasure fleets in particular. After independence, trade among the new Spanish American nations was less than it had been in the colonial period. Once the ties were broken, the small populations of most of the new nations provided little incentive to entice Spanish American producers to recreate the old trade patterns. In addition, the protection against European competition, which the Spanish monopoly had provided to the manufacturing sectors of the economy, ended. Due to expediency, protective tariffs for these sectors, in particular textile production, were permanently dropped and foreign imports beat out local production. This greatly affected Native communities, which in many parts of Spanish America, specialized in supplying finished products to the urban markets, albeit using pre-industrial-quarters in Mexico. Cities dependent on seaborne trade like Valdivia plunged into depression as the intracolonial trade system collapsed. Foreign trade policies varied among the new countries, some like the United Provinces of the Río de la Plata and Peru applied initially protectionist policies while Chile was more open to foreign trade while still applying a kind of neomercantilism.
Each coordinated water molecule may be attached by hydrogen bonds to other water molecules. The latter are said to reside in the second coordination sphere. However, for the alkali metal cations, the second coordination sphere is not well-defined as the +1 charge on the cation is not high enough to polarise the water molecules in the primary solvation shell enough for them to form strong hydrogen bonds with those in the second coordination sphere, producing a more stable entity. The solvation number for Li+ has been experimentally determined to be 4, forming the tetrahedral [Li(H2O)4]+: while solvation numbers of 3 to 6 have been found for lithium aqua ions, solvation numbers less than 4 may be the result of the formation of contact ion pairs, and the higher solvation numbers may be interpreted in terms of water molecules that approach [Li(H2O)4]+ through a face of the tetrahedron, though molecular dynamic simulations may indicate the existence of an octahedral hexaaqua ion. There are also probably six water molecules in the primary solvation sphere of the sodium ion, forming the octahedral [Na(H2O)6]+ ion. While it was previously thought that the heavier alkali metals also formed octahedral hexaaqua ions, it has since been found that potassium and rubidium probably form the [K(H2O)8]+ and [Rb(H2O)8]+ ions, which have the square antiprismatic structure, and that caesium forms the 12-coordinate [Cs(H2O)12]+ ion.
=== Distilled absinthe === Distilled absinthe employs a method of production similar to that of high-quality gin. Botanicals are initially macerated in distilled base alcohol before being redistilled to exclude bitter principles, and impart the desired complexity and texture to the spirit. The distillation of absinthe first yields a colourless distillate that leaves the alembic at around 72% ABV. The distillate may be reduced and bottled clear, to produce a Blanche or la Bleue absinthe, or it may be coloured to create a verte using natural or artificial colouring. Traditional absinthes obtain their green color strictly from the chlorophyll of whole herbs, which is extracted from the plants during the secondary maceration. This step involves steeping plants such as petite wormwood, hyssop, and melissa (among other herbs) in the distillate. Chlorophyll from these herbs is extracted, giving the drink its famous green color. This step also provides a herbal complexity that is typical of high-quality absinthe. The natural coloring process is critical for absinthe ageing since the chlorophyll remains chemically active. The chlorophyll serves a similar role in absinthe as tannins do in wine or brown liquors. After the coloring process, the resulting product is diluted with water to the desired alcohol percentage. The flavor of absinthe is said to improve materially with storage, and many distilleries, before the ban, aged their absinthe in settling tanks before bottling.
== Protein == The expressed peptide contains a three-turn α-helix, and has no symmetry. The length of the peptide depends on where it is produced. If it is produced inside the mitochondria it will be 21 amino acids long. If it is produced outside the mitochondria, in the cytosol, it will be 24 amino acids long. Both peptides have been shown to have biological activity. The full length 24 amino acid version of humanin has the sequence MAPRGFSCLLLLTSEIDLPVKRRA, with four residues cleaved from the C terminal end to form the 20 amino acid mitochondrial version MAPRGFSCLLLLTSEIDLPV. Several other natural isoforms are also known with slight variations to the amino acid sequence. Synthetic versions often have one or more amino acid changes to increase stability and improve activity, such as HNG with a S→G substitution at position 14, and HNGF6A which has an F→A substitution at position 6 as well. Humanin-glycine (HNG) is up to 1000x more potent than the natural version depending how the activity is assayed, and so is one of the more common synthetic analogues used in research and investigated for potential clinical applications. Shorter fragments such as HN(1-19) and HN(1-17) also retain some activity but are generally less potent.
Sources: en.wikipedia.org
=== Topical use === The most common adverse events associated with the use of topical tacrolimus ointments, especially if used over a wide area, include a burning or itching sensation on the initial applications, with increased sensitivity to sunlight and heat on the affected areas. Less common are flu-like symptoms, headache, cough, and burning eyes.
=== 1989 === January 4: Gulf of Sidra incident between America and Libya, similar to the 1981 Gulf of Sidra incident. January 7: Emperor Hirohito dies, marking the end of the Showa era in Japan. January 11: Communist Hungary introduces political reforms. January 19: The trade union Solidarity is legalized by the Polish government. January 20: George H. W. Bush is inaugurated as 41st President of the United States. February 2: Soviet troops withdraw from Afghanistan. February 3: Alfredo Stroessner was deposed in a coup led by Andrés Rodríguez. February 14: The Contra war effectively ends with the Tesoro Beach Accords happening in El Salvador with Costa Rica, El Salvador, Guatemala, Honduras and Nicaragua participating. An agreement is made that all contra forces are to disband in return for a free election to be held in February 1990. Although a few groups initially reject the agreement they eventually decide to participate. February 15: The Afghan Civil War begins after Soviet troops withdrawing from Afghanistan. February 19–21: Jakarta Informal Meeting II was held in Jakarta. This meeting succeeded in finding two important issues, namely the withdrawal of Vietnamese troops from Cambodia and the prevention of the return of the Pol Pot regime in Cambodia. Later, efforts to resolve the conflict will continue in International Conference in Paris on July 30–31, 1989. March 26: The Soviet Union holds the first round of legislative elections to the Congress of People's Deputies. June 3: Ayatollah Khomeini dies.
=== As a drug target === The YAP1 oncogene serves as a target for the development of new cancer drugs. Small compounds have been identified that disrupt the YAP1-TEAD complex or block the binding function of WW domains. These small molecules represent lead compounds for the development of therapies for cancer patients, who harbor amplified or overexpressed YAP oncogene.
== Quantification == Quantifying vasculature parameters such as microvascular density has various complications due to preferential staining or limited representation of tissues by histological sections. Recent research has shown complete 3D reconstruction of tumor vascular structure and quantification of vessel structures in whole tumors in animal models.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.